3 Strong Oncology & Specialty Momentum: Beyond neuroscience, BMSs growth portfolio delivered $6.9B, led by: OPDIVO (nivolumab) US HCP: $2.5B (+8%) Breyanzi (lisocabtagene maraleucel) HCP: $359M (+58%) CAMZYOS (mavacamten) US HCP: $296M (+88%) These results reinforce BMSs transformation into a data-rich, diversified biopharma, with pivotal readouts expected in 2026 across fibrosis, multiple myeloma, and autoimmune indications
Patere, S
Neurobiology and therapeutic potential of 5-GABA type a receptors
In particular, WKY rats show marked changes in the distribution and density of dopamine transporters (DAT) and DA receptors (D1, D2, D3) within the mesolimbic system, leading to attenuated tissue DA levels in Hip, PFC, NAc shell, and BLA
When administered therapeutically, GLP-1 receptor agonists work through several mechanisms: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner [1] [4] Suppressing glucagon release from alpha cells, reducing hepatic glucose output Slowing gastric emptying , which helps moderate post-meal blood glucose rises Promoting satiety through central nervous system pathways, potentially supporting weight reduction Investigational transdermal GLP-1 delivery systems typically utilise specialised technologies such as microneedles or active delivery methods rather than conventional patches, as GLP-1 molecules are large peptides that do not easily penetrate the skin barrier
The FDA no longer lets companies sell generic semaglutide because the shortage of name-brand drugs such as Ozempic has ended